These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 35432799)

  • 1. Ischemic post-conditioning is neuroprotective even at delayed tPA administration after embolic stroke in female rats.
    Mohammadi M; Mobini M; Mashayekhi F; Allahtavakoli M; Kaeidi A; Hassanshahi J; Shamsizadeh A; Hakimizadeh E; Hassanipour M
    Iran J Basic Med Sci; 2021 Dec; 24(12):1676-1682. PubMed ID: 35432799
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Opening the window: Ischemic postconditioning reduces the hyperemic response of delayed tissue plasminogen activator and extends its therapeutic time window in an embolic stroke model.
    Esmaeeli-Nadimi A; Kennedy D; Allahtavakoli M
    Eur J Pharmacol; 2015 Oct; 764():55-62. PubMed ID: 26123846
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Whole body hypothermia extends tissue plasminogen activator treatment window in the rat model of embolic stroke.
    Hassanipour M; Zarisfi M; Ehsani V; Allahtavakoli M
    Life Sci; 2020 Sep; 256():117450. PubMed ID: 32087233
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Transient brain hypothermia reduces the reperfusion injury of delayed tissue plasminogen activator and extends its therapeutic time window in a focal embolic stroke model.
    Zarisfi M; Allahtavakoli F; Hassanipour M; Khaksari M; Rezazadeh H; Allahtavakoli M; Taghavi MM
    Brain Res Bull; 2017 Sep; 134():85-90. PubMed ID: 28710023
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combination treatment with low-dose Niaspan and tissue plasminogen activator provides neuroprotection after embolic stroke in rats.
    Shehadah A; Chen J; Cui Y; Zhang L; Roberts C; Lu M; Chopp M
    J Neurol Sci; 2011 Oct; 309(1-2):96-101. PubMed ID: 21802695
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Adjuvant treatment with neuroserpin increases the therapeutic window for tissue-type plasminogen activator administration in a rat model of embolic stroke.
    Zhang Z; Zhang L; Yepes M; Jiang Q; Li Q; Arniego P; Coleman TA; Lawrence DA; Chopp M
    Circulation; 2002 Aug; 106(6):740-5. PubMed ID: 12163437
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Taurine Reduces tPA (Tissue-Type Plasminogen Activator)-Induced Hemorrhage and Microvascular Thrombosis After Embolic Stroke in Rat.
    Jin R; Xiao AY; Liu S; Wang M; Li G
    Stroke; 2018 Jul; 49(7):1708-1718. PubMed ID: 29844028
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Normobaric hyperoxia reduces the neurovascular complications associated with delayed tissue plasminogen activator treatment in a rat model of focal cerebral ischemia.
    Liu W; Hendren J; Qin XJ; Liu KJ
    Stroke; 2009 Jul; 40(7):2526-31. PubMed ID: 19478225
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Vepoloxamer Enhances Fibrinolysis of tPA (Tissue-Type Plasminogen Activator) on Acute Ischemic Stroke.
    Wang C; Huang R; Li C; Lu M; Emanuele M; Zhang ZG; Chopp M; Zhang L
    Stroke; 2019 Dec; 50(12):3600-3608. PubMed ID: 31587657
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combination treatment with VELCADE and low-dose tissue plasminogen activator provides potent neuroprotection in aged rats after embolic focal ischemia.
    Zhang L; Zhang ZG; Buller B; Jiang J; Jiang Y; Zhao D; Liu X; Morris D; Chopp M
    Stroke; 2010 May; 41(5):1001-7. PubMed ID: 20203318
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ascorbic Acid Reduces the Adverse Effects of Delayed Administration of Tissue Plasminogen Activator in a Rat Stroke Model.
    Allahtavakoli M; Amin F; Esmaeeli-Nadimi A; Shamsizadeh A; Kazemi-Arababadi M; Kennedy D
    Basic Clin Pharmacol Toxicol; 2015 Nov; 117(5):335-9. PubMed ID: 25899606
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Matrix metalloproteinase activation and blood-brain barrier breakdown following thrombolysis.
    Kelly MA; Shuaib A; Todd KG
    Exp Neurol; 2006 Jul; 200(1):38-49. PubMed ID: 16624294
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of erythropoietin combined with tissue plasminogen activator on the rats following cerebral ischemia and reperfusion.
    Wang R; Wu X; Zhao H; Min L; Tao Z; Ji X; Luo Y
    Brain Circ; 2016; 2(1):54-60. PubMed ID: 30276273
    [TBL] [Abstract][Full Text] [Related]  

  • 14. THR-18, a 18-mer peptide derived from PAI-1, is neuroprotective and improves thrombolysis by tPA in rat stroke models.
    Krakovsky M; Polianski V; Nimrod A; Higazi A; Leker RR; Lamensdorf I
    Neurol Res; 2011 Nov; 33(9):983-90. PubMed ID: 22081002
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Candesartan reduces the hemorrhage associated with delayed tissue plasminogen activator treatment in rat embolic stroke.
    Ishrat T; Pillai B; Ergul A; Hafez S; Fagan SC
    Neurochem Res; 2013 Dec; 38(12):2668-77. PubMed ID: 24194350
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment of stroke in aged male and female rats with Vepoloxamer and tPA reduces neurovascular damage.
    Zhang L; Luo H; Li C; Teng H; Powell B; Lu M; Chopp M; Zhang ZG
    Front Neurol; 2023; 14():1282736. PubMed ID: 37869138
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Normobaric hyperoxia slows blood-brain barrier damage and expands the therapeutic time window for tissue-type plasminogen activator treatment in cerebral ischemia.
    Liang J; Qi Z; Liu W; Wang P; Shi W; Dong W; Ji X; Luo Y; Liu KJ
    Stroke; 2015 May; 46(5):1344-1351. PubMed ID: 25804925
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Therapeutic benefits of combined treatment with tissue plasminogen activator and 2-(4-methoxyphenyl)ethyl-2-acetamido-2-deoxy-β-d-pyranoside in an animal model of ischemic stroke.
    Yu S; Liu X; Shen Y; Xu H; Yang Y; Ding F
    Neuroscience; 2016 Jul; 327():44-52. PubMed ID: 27060484
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of ML351 and tissue plasminogen activator combination therapy in a rat model of focal embolic stroke.
    Cheng G; Zhao W; Xin Y; Huang G; Liu Y; Li Z; Zhan M; Li Y; Lu L; van Leyen K; Liu Y
    J Neurochem; 2021 May; 157(3):586-598. PubMed ID: 33481248
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Early administration of pyrrolidine dithiocarbamate extends the therapeutic time window of tissue plasminogen activator in a male rat model of embolic stroke.
    Wang Z; Shan W; Cao J; Wintermark M; Huang W; Zuo Z
    J Neurosci Res; 2018 Mar; 96(3):449-458. PubMed ID: 28976017
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.